765 related articles for article (PubMed ID: 31126818)
21. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
22. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
Chen D; Luo L; Liang C
PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
[TBL] [Abstract][Full Text] [Related]
23. LDH-A promotes malignant behavior via activation of epithelial-to-mesenchymal transition in lung adenocarcinoma.
Hou XM; Yuan SQ; Zhao D; Liu XJ; Wu XA
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30509961
[TBL] [Abstract][Full Text] [Related]
24. Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis.
Sun D; Zhu Y; Zhao H; Bian T; Li T; Liu K; Feng L; Li H; Hou H
Cell Oncol (Dordr); 2021 Oct; 44(5):1019-1034. PubMed ID: 34109546
[TBL] [Abstract][Full Text] [Related]
25. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
26. Role of endothelin receptor type B (EDNRB) in lung adenocarcinoma.
Wei F; Ge Y; Li W; Wang X; Chen B
Thorac Cancer; 2020 Jul; 11(7):1885-1890. PubMed ID: 32394530
[TBL] [Abstract][Full Text] [Related]
27. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
Zhu HE; Yin JY; Chen DX; He S; Chen H
Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
[TBL] [Abstract][Full Text] [Related]
28. KIF18B as a regulator in microtubule movement accelerates tumor progression and triggers poor outcome in lung adenocarcinoma.
Ji Z; Pan X; Shang Y; Ni DT; Wu FL
Tissue Cell; 2019 Dec; 61():44-50. PubMed ID: 31759406
[TBL] [Abstract][Full Text] [Related]
29. FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.
Liu C; Li Z; Wang S; Fan Y; Zhang S; Yang X; Hou K; Tong J; Hu X; Shi X; Wang X; Liu Y; Che X; Qu X
J Cancer Res Clin Oncol; 2019 Jan; 145(1):65-76. PubMed ID: 30357521
[TBL] [Abstract][Full Text] [Related]
30. Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway.
Liang J; Li H; Han J; Jiang J; Wang J; Li Y; Feng Z; Zhao R; Sun Z; Lv B; Tian H
Cell Death Dis; 2020 Aug; 11(8):614. PubMed ID: 32792503
[TBL] [Abstract][Full Text] [Related]
31. GALNT2 promotes cell proliferation, migration, and invasion by activating the Notch/Hes1-PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma.
Wang W; Sun R; Zeng L; Chen Y; Zhang N; Cao S; Deng S; Meng X; Yang S
Life Sci; 2021 Jul; 276():119439. PubMed ID: 33785338
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of microsomal glutathione S-transferase 1 inhibits lung adenocarcinoma cell proliferation and induces apoptosis.
Zeng B; Ge C; Li R; Zhang Z; Fu Q; Li Z; Lin Z; Liu L; Xue Y; Xu Y; He J; Guo H; Li C; Huang W; Song X; Huang Y
Biomed Pharmacother; 2020 Jan; 121():109562. PubMed ID: 31707341
[TBL] [Abstract][Full Text] [Related]
33. LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma.
Yu C; Hou L; Cui H; Zhang L; Tan X; Leng X; Li Y
Future Oncol; 2018 Oct; 14(24):2483-2492. PubMed ID: 29756998
[TBL] [Abstract][Full Text] [Related]
34. p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma.
Gu MM; Gao D; Yao PA; Yu L; Yang XD; Xing CG; Zhou J; Shang ZF; Li M
Cancer Sci; 2018 Dec; 109(12):3783-3793. PubMed ID: 30281878
[TBL] [Abstract][Full Text] [Related]
35. CHPF promotes lung adenocarcinoma proliferation and anti-apoptosis via the MAPK pathway.
Hou XM; Zhang T; Da Z; Wu XA
Pathol Res Pract; 2019 May; 215(5):988-994. PubMed ID: 30826152
[TBL] [Abstract][Full Text] [Related]
36. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
Zhang J; Sun G; Mei X
Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
[TBL] [Abstract][Full Text] [Related]
37. CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway.
Zhang H; Cao Y; Tang J; Wang R
Biomed Res Int; 2022; 2022():9944847. PubMed ID: 35813221
[TBL] [Abstract][Full Text] [Related]
38. [S100A10 promotes proliferation and invasion of lung adenocarcinoma cells by activating the Akt-mTOR signaling pathway].
Wang H; Sun Z; Zhao W; Geng B
Nan Fang Yi Ke Da Xue Xue Bao; 2023 May; 43(5):733-740. PubMed ID: 37313814
[TBL] [Abstract][Full Text] [Related]
39. Ferredoxin 1: a gatekeeper in halting lung adenocarcinoma progression through activation of the GPRIN2 signaling pathway.
Liu M; Wu S; Wu H; Zhou Y; Zhang X; Zhu D; Jiang J
J Transl Med; 2024 May; 22(1):510. PubMed ID: 38802900
[TBL] [Abstract][Full Text] [Related]
40. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
